; (2) the name of the recipient drug; and (3) the duration of the conveyed exclusivity extension period. (c) Effect of conveyance (1) Extension of other applicable exclusivity periods Immediately upon the Secretary’s receipt of a notice under subsection (b), with respect to the recipient drug, the following exclusivity periods (as applicable) are each extended by the conveyed exclusivity extension period: (A) The 4-year, 5-year, 48-month, and 7½-year periods described in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 505. (B) The 3-year periods described in clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 505. (C) The 7-year period described in section 527. (2) Drugs subject to listed patents Immediately upon the Secretary’s receipt of a notice under subsection (b), the period during which an approval of an application may not be made effective by operation of subsection (c)(3) or (j)(5)(B) of section 505, as applicable, in the case of a recipient drug that is the subject of— (A) a listed patent for which a certification has been submitted under subsection (b)(2)(A)(ii) or (j)(2)(A)(vii)(II) of section 505; (B) a listed patent for which a certification has been submitted under subsection (b)(2)(A)(iii) or (j)(2)(A)(vii)(III) of section 505